Related Experiment Videos
Perhexiline maleate-induced hepatitis
Hepato-Gastroenterology
|August 1, 1991
Abstract:
We report on a case of perhexiline maleate-induced hepatitis secondary to a long-term administration of recommended daily dosages of 300 mg. The patient had a spectacular weight loss of 29 kg. He developed hepatitis, which subsided after drug withdrawal. Our electron-microscopic findings with the typical inclusion bodies and impaired hydroxylation capacity point to an underlying metabolic disorder as the pathogenetic mechanism.
Insights
Perhexiline maleate caused drug-induced hepatitis in a patient taking 300 mg daily. Symptoms resolved after discontinuing the medication, suggesting a metabolic link.
Area of Science:
- Hepatology
- Pharmacology
- Toxicology
Background:
- Perhexiline maleate is a medication used for angina.
- Long-term use can lead to adverse effects.
- Hepatotoxicity is a potential concern.
Observation:
- A patient experienced significant weight loss (29 kg).
- Hepatitis developed during perhexiline maleate therapy.
- Symptoms improved upon drug cessation.
Findings:
- Electron microscopy revealed characteristic inclusion bodies.
- Impaired hydroxylation capacity was observed.
- These findings suggest a metabolic disorder in pathogenesis.
Implications:
- This case highlights perhexiline maleate's potential for drug-induced liver injury.
- Metabolic pathways may play a crucial role in perhexiline toxicity.
- Further research into metabolic mechanisms of drug-induced hepatitis is warranted.